PDC*line Pharma

Eric Halioua, President and CEO
Liège, Belgium
PDC*line Pharma is a clinical-stage cell therapy company that develops a new class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line). Based on a robust preclinical package and a first-in-human Phase Ib in melanoma, PDC*line Pharma is initiating a clinical development in lung cancer with a new candidate (PDC*lung) and neoantigens (PDC*Neo). PDC*line Pharma comprises a team of 23 persons based in Liège, Belgium and in Grenoble, France. The company has raised nearly €32M. In March 2019, PDC*line Pharma was granted an exclusive license in South Korea and an exclusive option in other Asian countries to LG Chem, for the development and commercialization of PDC*lung cancer vaccine for lung cancer. The total deal value is 108M€ plus significant tiered royalties on net sales in Asia.

By using this website you agree to accept our Privacy Policy and Terms & Conditions